Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Retained Earnings (2023 - 2025)

Immunome's Retained Earnings history spans 3 years, with the latest figure at -$728.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 41.18% year-over-year to -$728.2 million; the TTM value through Dec 2025 reached -$728.2 million, down 41.18%, while the annual FY2025 figure was -$728.2 million, 41.18% down from the prior year.
  • Retained Earnings reached -$728.2 million in Q4 2025 per IMNM's latest filing, down from -$658.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$120.3 million in Q1 2023 to a low of -$728.2 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$403.0 million, with a median of -$412.0 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: plummeted 234.55% in 2024, then crashed 41.18% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$222.8 million in 2023, then crashed by 131.49% to -$515.8 million in 2024, then tumbled by 41.18% to -$728.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Retained Earnings are -$728.2 million (Q4 2025), -$658.3 million (Q3 2025), and -$600.8 million (Q2 2025).